Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy

Clinical Trial ID NCT01061970

Rank	Title	Journal	Year	PubWeight™‹?›
1	Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.	Am J Respir Crit Care Med	2001	27.83
2	Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease.	Am J Respir Crit Care Med	2004	1.91
3	Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease.	Am J Respir Crit Care Med	2005	1.61
4	Catabolic/anabolic balance and muscle wasting in patients with COPD.	Chest	2003	1.54
5	Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial.	Respir Med	2004	1.51
6	Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial.	Am J Respir Crit Care Med	1995	1.25
7	Systemic effects in COPD.	Chest	2002	1.19
8	Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy.	Eur Respir J	1998	0.97
9	The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients.	Chest	1998	0.95
10	Reversal of COPD-associated weight loss using the anabolic agent oxandrolone.	Chest	2002	0.85